Equity Overview
Price & Market Data
Price: $1.28
Daily Change: +$0.11 / 8.59%
Range: $1.16 - $1.28
Market Cap: $13,707,520
Volume: 28,747
Performance Metrics
1 Week: 14.35%
1 Month: 3.78%
3 Months: -46.77%
6 Months: -66.62%
1 Year: -70.53%
YTD: -60.29%
Company Details
Employees: 5
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.